---
layout: post
title: "Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V"
date: 2026-02-05 19:01:28 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-24157
original_published: 2022-11-09 00:00:00 +0000
significance: 8.00
---

# Schedules of Controlled Substances: Placement of Ganaxolone in Schedule V

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** November 09, 2022 00:00 UTC
**Document Number:** 2022-24157

## Summary

This final rule adopts, without change, an interim final rule with request for comments published in the Federal Register on June 1, 2022, placing ganaxolone (3[alpha]-hydroxy-3[beta]-methyl-5[alpha]- pregnan-20-one) and its salts in schedule V of the Controlled Substances Act. With the issuance of this final rule, the Drug Enforcement Administration maintains ganaxolone, including its salts, in schedule V of the Controlled Substances Act.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/11/09/2022-24157/schedules-of-controlled-substances-placement-of-ganaxolone-in-schedule-v)
- API: https://www.federalregister.gov/api/v1/documents/2022-24157

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
